Pharmaceuticals, Biotech & Life Sciences Brands · Advertiser / Brand
Galderma
Global dermatology company spanning therapeutics, aesthetics and skincare.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Galderma Group AG
- Entity type
- COMPANY
- Founded
- 1981
- Headquarters
- Zählerweg 10, 6300 Zug, Switzerland
- Company size
- >5,000
- Market cluster / sector
- Pharmaceuticals, Biotech & Life Sciences Brands
- Market role
- Advertiser / Brand
- Ticker
- GALD (SIX)
- Official website
- galderma.com
What Galderma does
Galderma creates value by researching, developing, manufacturing and commercialising dermatology-focused products across prescription therapeutics, injectable aesthetics and skincare. It monetises this portfolio through product sales into professional healthcare channels and consumer skincare channels, using brand equity, clinical positioning and global distribution to drive repeat demand.
Category differentiation
Galderma is a dermatology products company, not an adtech, martech or software platform. It operates as a skin-health manufacturer and brand spanning therapeutics, aesthetics and skincare.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Galderma Group AG is a publicly listed pure-play dermatology company headquartered in Switzerland. It develops and sells prescription therapeutics, injectable aesthetic treatments and dermatological skincare products. The company operates globally and reported FY2025 net sales of USD 5.207 billion, indicating large-scale commercial execution across medical and consumer skin-health segments. Galderma generates revenue by selling branded dermatology products through healthcare, aesthetics and skincare channels. Its customers include dermatologists, aesthetic physicians and clinics, pharmacies, distributors, retailers and end-consumers purchasing skincare products. The business model combines medical-product sales with aesthetics and skincare demand, giving it exposure to both clinician-driven and consumer-led spending.
Company news briefing
Briefing updated:
Galderma has inaugurated its new United States and Latin America headquarters in Miami, while marking a major corporate milestone by beginning to trade in the Swiss Market Index alongside Switzerland's leading blue-chip companies. Additionally, the company presented new clinical data at EADV 2026 demonstrating sustained three-year improvements with Nemluvio® for atopic dermatitis patients.
Business model & monetisation
Galderma primarily monetises through product sales. Revenue comes from prescription therapeutics sold via medical channels, injectable aesthetic treatments sold to clinics and physicians, and dermatological skincare sold through retail, pharmacy and professional channels. The commercial model is based on recurring replenishment and repeat purchase rather than subscriptions or advertising.
- Dermatological product sales
- One-time Sale
- Injectable aesthetic treatment sales
- One-time Sale
- Dermatological skincare sales
- One-time Sale
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Galderma
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Galderma's competitive landscape.
Global family-owned healthcare group spanning aesthetics, therapeutics and lifecare.
French dermo-cosmetics group behind three skincare brands.
Global beauty brand selling cosmetics, skincare, haircare and fragrance.
Prestige beauty group selling skincare, make-up, fragrance and haircare.
Biopharmaceutical company developing and commercialising prescription medicines.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older
Recorded impact score: 2/5
Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.
EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis
Recorded impact score: 4/5
Galderma announced new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) provides sustained improvements in moderate-to-severe atopic dermatitis for up to 152 weeks. At Week 152, up to 91% of patients achieved EASI-75, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life. The findings were presented at the EADV 2026 Congress in Vienna, Austria, which runs September 30 to October 3, 2026. Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis in more than 40 countries.
- Galderma published the press release on September 30, 2026, announcing new three-year ARCADIA long-term extension data for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis.
- At Week 152, up to 91% of patients achieved EASI-75, up to 75% achieved EASI-90, up to 67% achieved IGA 0/1, up to 88% achieved clinically meaningful itch relief, and up to 92% achieved clinically meaningful quality-of-life improvement.
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies
Recorded impact score: 4.5/5
Galderma has been added to the Swiss Market Index (SMI), marking its inclusion among Switzerland's leading blue-chip companies. This is a major corporate milestone for the company.
Galderma opens new U.S. and Latin America headquarters in Miami
Recorded impact score: 4/5
Explore company relationships
Questions about Galderma
What is Galderma?
Galderma is a publicly listed pure-play dermatology company that develops and sells prescription therapeutics, injectable aesthetic treatments and dermatological skincare products.
Who uses Galderma?
Galderma serves dermatologists, aesthetic physicians, clinics, pharmacies, retailers, distributors and consumers who buy skincare products.
How does Galderma make money?
Galderma makes money by selling dermatology products across therapeutic, injectable aesthetics and skincare categories through medical and consumer channels.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
11 publicly documented primary sources and citations linked across the market graph.
Continue your research on Galderma
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals